MX2010010270A - Metodo de prueba de solucion de dialisis peritoneal. - Google Patents
Metodo de prueba de solucion de dialisis peritoneal.Info
- Publication number
- MX2010010270A MX2010010270A MX2010010270A MX2010010270A MX2010010270A MX 2010010270 A MX2010010270 A MX 2010010270A MX 2010010270 A MX2010010270 A MX 2010010270A MX 2010010270 A MX2010010270 A MX 2010010270A MX 2010010270 A MX2010010270 A MX 2010010270A
- Authority
- MX
- Mexico
- Prior art keywords
- assay
- response
- glucose polymer
- proinflammatory response
- expressed
- Prior art date
Links
- 239000000385 dialysis solution Substances 0.000 title claims description 87
- 238000010998 test method Methods 0.000 title abstract description 4
- 230000007112 pro inflammatory response Effects 0.000 claims abstract description 92
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 91
- 239000008103 glucose Substances 0.000 claims abstract description 91
- 229920000642 polymer Polymers 0.000 claims abstract description 88
- 239000012465 retentate Substances 0.000 claims abstract description 58
- 238000003556 assay Methods 0.000 claims abstract description 54
- 239000000706 filtrate Substances 0.000 claims abstract description 49
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 24
- 230000004044 response Effects 0.000 claims description 81
- 238000012360 testing method Methods 0.000 claims description 68
- 238000000034 method Methods 0.000 claims description 49
- 102000004889 Interleukin-6 Human genes 0.000 claims description 46
- 108090001005 Interleukin-6 Proteins 0.000 claims description 46
- 229940100601 interleukin-6 Drugs 0.000 claims description 46
- 238000000502 dialysis Methods 0.000 claims description 36
- 238000001914 filtration Methods 0.000 claims description 36
- 229920002177 Icodextrin Polymers 0.000 claims description 24
- 229940016836 icodextrin Drugs 0.000 claims description 24
- 102000000589 Interleukin-1 Human genes 0.000 claims description 13
- 108010002352 Interleukin-1 Proteins 0.000 claims description 13
- 210000004027 cell Anatomy 0.000 claims description 12
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims description 9
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 6
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 102000009571 Macrophage Inflammatory Proteins Human genes 0.000 claims description 5
- 108010009474 Macrophage Inflammatory Proteins Proteins 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000000770 proinflammatory effect Effects 0.000 claims description 4
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims description 2
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims 2
- 210000004976 peripheral blood cell Anatomy 0.000 claims 1
- 239000000243 solution Substances 0.000 description 27
- 239000000523 sample Substances 0.000 description 24
- 239000000356 contaminant Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 20
- 206010071648 Noninfectious peritonitis Diseases 0.000 description 18
- 102000004127 Cytokines Human genes 0.000 description 16
- 108090000695 Cytokines Proteins 0.000 description 16
- 238000010586 diagram Methods 0.000 description 14
- 239000000463 material Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000002357 osmotic agent Substances 0.000 description 8
- 239000002253 acid Substances 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 206010034674 peritonitis Diseases 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 6
- 108010013639 Peptidoglycan Proteins 0.000 description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000000717 retained effect Effects 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 238000004891 communication Methods 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 4
- 102000003814 Interleukin-10 Human genes 0.000 description 4
- 108090000174 Interleukin-10 Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000000470 constituent Substances 0.000 description 4
- 239000003792 electrolyte Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 229940076144 interleukin-10 Drugs 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000001631 haemodialysis Methods 0.000 description 3
- 230000000322 hemodialysis Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- 239000003330 peritoneal dialysis fluid Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229940107700 pyruvic acid Drugs 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 208000020832 chronic kidney disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 150000002303 glucose derivatives Chemical class 0.000 description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 description 2
- -1 lactic acid Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000012569 microbial contaminant Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940076788 pyruvate Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000012959 renal replacement therapy Methods 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012956 testing procedure Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 239000004368 Modified starch Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000002615 hemofiltration Methods 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4722—Proteoglycans, e.g. aggreccan
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
- G01N2333/5412—IL-6
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/052,446 US20090239819A1 (en) | 2008-03-20 | 2008-03-20 | Peritoneal dialysis solution test method |
| PCT/US2009/036940 WO2009117304A1 (en) | 2008-03-20 | 2009-03-12 | Peritoneal dialysis solution test method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010010270A true MX2010010270A (es) | 2010-12-02 |
Family
ID=40785585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010010270A MX2010010270A (es) | 2008-03-20 | 2009-03-12 | Metodo de prueba de solucion de dialisis peritoneal. |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20090239819A1 (enExample) |
| EP (1) | EP2268830B2 (enExample) |
| JP (2) | JP5628786B2 (enExample) |
| MX (1) | MX2010010270A (enExample) |
| WO (1) | WO2009117304A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102010012281A1 (de) | 2010-03-22 | 2011-09-22 | Fresenius Medical Care Deutschland Gmbh | Pharmazeutische Zusammensetzungen enthaltend substituiertes 6-Deoxy-6-sulfanylcyclodextrin |
| FR2978774B1 (fr) * | 2011-08-02 | 2015-02-20 | Roquette Freres | Methodes de detection des contaminants des circuits de production de polymeres de glucose |
| JP5989088B2 (ja) | 2011-04-08 | 2016-09-07 | ロケット フレールＲｏｑｕｅｔｔｅ Ｆｒｅｒｅｓ | グルコースポリマーに含まれる汚染物質の検出方法 |
| JP6244356B2 (ja) * | 2012-05-29 | 2017-12-06 | ロケット フレールＲｏｑｕｅｔｔｅ Ｆｒｅｒｅｓ | グルコースポリマーおよびグルコースポリマー加水分解物の製造回路の除染方法 |
| WO2014154651A1 (fr) * | 2013-03-26 | 2014-10-02 | Roquette Freres | Dosage biologique des peptidoglycanes |
| JP6284651B2 (ja) | 2014-03-21 | 2018-02-28 | ロケット フレールＲｏｑｕｅｔｔｅ Ｆｒｅｒｅｓ | グルコースポリマーおよびグルコースポリマー加水分解物の生成物を汚染除去するための最適化された方法 |
| FR3037063B1 (fr) | 2015-06-04 | 2017-05-19 | Roquette Freres | Procede optimise de decontamination de l'amidon utilise comme matiere premiere pour l'obtention de polymeres de glucose destines a la dialyse peritoneale |
| CN105131135B (zh) * | 2015-09-17 | 2018-08-14 | 四川博佳制药有限公司 | 艾考糊精的工业化生产方法 |
| US11116881B2 (en) | 2016-05-27 | 2021-09-14 | Cook Medical Technologies Llc | Filtration system and process for peritoneal dialysis |
| EP3786618A1 (en) * | 2019-08-26 | 2021-03-03 | Veterinärmedizinische Universität Wien | A method for analyzing a peritoneal dialysis sample |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU73094A1 (enExample) * | 1975-07-29 | 1977-03-24 | ||
| US5731164A (en) * | 1991-08-06 | 1998-03-24 | Sanorell Pharma Gmbh & Co. | method of checking the rate of removal of pyrogenic substances, in particular viruses, from organic material |
| US7118857B2 (en) * | 2004-02-27 | 2006-10-10 | Baxter International Inc. | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions |
| EP1977252B1 (en) | 2005-12-22 | 2012-12-05 | Baxter International Inc. | Improved monocyte activation test better able to detect non-endotoxin pyrogenic contaminants in medical products |
| WO2008009292A1 (en) * | 2006-07-18 | 2008-01-24 | Kobenhavns Universitet | An in vitro method for detection of inflammatory contaminants |
-
2008
- 2008-03-20 US US12/052,446 patent/US20090239819A1/en not_active Abandoned
-
2009
- 2009-03-12 MX MX2010010270A patent/MX2010010270A/es active IP Right Grant
- 2009-03-12 WO PCT/US2009/036940 patent/WO2009117304A1/en not_active Ceased
- 2009-03-12 JP JP2011500873A patent/JP5628786B2/ja active Active
- 2009-03-12 EP EP09721862.2A patent/EP2268830B2/en active Active
-
2014
- 2014-07-17 JP JP2014146508A patent/JP2014197033A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009117304A1 (en) | 2009-09-24 |
| JP2014197033A (ja) | 2014-10-16 |
| EP2268830B1 (en) | 2012-05-16 |
| EP2268830B2 (en) | 2016-06-15 |
| JP2011517405A (ja) | 2011-06-09 |
| US20090239819A1 (en) | 2009-09-24 |
| EP2268830A1 (en) | 2011-01-05 |
| JP5628786B2 (ja) | 2014-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2268830B1 (en) | Peritoneal dialysis solution test method | |
| JP2011517405A5 (enExample) | ||
| Kato et al. | Elevation of blood (1→ 3)-beta-D-glucan concentrations in hemodialysis patients | |
| JP5334412B2 (ja) | 腹膜透析溶液中の微生物汚染物を検出するための方法および組成物 | |
| JP6436958B2 (ja) | 腹膜透析用グルコースポリマーを調製するためのデンプン加水分解物を汚染除去する方法 | |
| JP6310973B2 (ja) | グルコースポリマーに含まれる汚染物質の検出方法 | |
| US20200400650A1 (en) | Methods for decontaminating circuits for producing glucose polymers and hydrolysates of glucose polymers | |
| Nisbeth et al. | Endotoxemia in chronic renal failure | |
| EP2273995B2 (en) | Destruction of microbial products by enzymatic digestion | |
| Klinkmann et al. | Clinical relevance of biocompatibility—the material cannot be divorced from the device | |
| Bhunyakarnjanarat et al. | Determination of the number of times for reuse of hemodialysis dialyzer through macrophage responses against dialyzer-eluted protein, a proposed method | |
| WO2009117303A1 (en) | Methods for measuring pro-inflammatory substance levels in dialysis solutions and dialysis components | |
| WO2009117302A1 (en) | Removal of substances in dialysis solutions and dialysis components by ion exchange adsorption | |
| FR2978774A1 (fr) | Methodes de detection des contaminants des circuits de production de polymeres de glucose | |
| Schambye et al. | Cytotoxicity of continuous ambulatory peritoneal dialysis (CAPD) solutions. A biocompatibility study involving human polymorphonuclear granulocytes rather than laboratory animals | |
| Sobhy | Pyrogens | |
| WO1995024206A1 (en) | Stroma, method of preparation thereof and its use in treatment of septic shock in mammals | |
| MXPA06009699A (en) | Methods and compositions for detection of microbial contaminants in peritoneal dialysis solutions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |